JoVE Logo
Faculty Resource Center

Sign In

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

DOI :

10.3791/50868-v

October 30th, 2013

October 30th, 2013

21,016 Views

1Department of Internal Medicine, Division of Hematology and Oncology, University of California, Davis, 2Comparative Pathology Laboratory, UC Davis School of Veterinary Medicine, University of California, Davis, 3Merck Serono Research, Merck KGaA, Darmstadt, Germany

An N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder cancer model was developed in human mucin 1 (MUC1) transgenic mice for the purpose of testing MUC1-directed immunotherapy. After administering a MUC1-targeted peptide vaccine, a cytotoxic T lymphocyte response to MUC1 was confirmed by measuring serum cytokine levels and T-cell specific activity.

Tags

Invasive Transitional Cell Bladder Carcinoma

-- Views

Related Videos

article

Establishment and Propagation of Human Retinoblastoma Tumors in Immune Deficient Mice

article

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

article

Protocol for Long Duration Whole Body Hyperthermia in Mice

article

The Use of Cystometry in Small Rodents: A Study of Bladder Chemosensation

article

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

article

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice

article

Facial Nerve Axotomy in Mice: A Model to Study Motoneuron Response to Injury

article

Induction of Accelerated Atherosclerosis in Mice: The "Wire-Injury" Model

article

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

article

A Minimally Invasive Model to Analyze Endochondral Fracture Healing in Mice Under Standardized Biomechanical Conditions

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved